Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy

Neuropsychopharmacology

Volumn 24, Issue 2, 2001, Pages 130-140

  Maes, Michael ^a,b,c,h   Capuron, Lucile ^d   Ravaud, Alain ^e,f   Gualde, Norbert ^e,f   Bosmans, Eugene ^a,g   Egyed, Belinda ^a   Dantzer, Robert ^d   Neveu, Pierre J ^d  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VANDERBILT UNIVERSITY   (United States)

^c Clinical Research Center for Mental Health of Antwerp   (Belgium)

^d INSERM   (France)

^e INSTITUT BERGONIÉ   (France)

^f CNRS Bordeaux Segalen University   (France)

^g Eurogenetics   (Belgium)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytokines; Depression; Dipeptidyl peptidase IV; Immunotherapy; Interferon; Interleukin 2

Indexed keywords

ALPHA INTERFERON; CYTOKINE; DIPEPTIDYL PEPTIDASE IV; INTERLEUKIN 2; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; ENZYME ACTIVITY; FEMALE; HUMAN; INFLAMMATION; MALE; METASTASIS; PRIORITY JOURNAL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGENS, CD26; ANTINEOPLASTIC AGENTS; CARCINOMA; CYTOKINES; DEPRESSION; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2;

EID: 0035195797     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00168-8     Document Type: Article

References (71)

1. Differential effects of interleukin (IL)-1beta, IL-2 and IL-6 on responding for rewarding lateral hypothalamic stimulation
2. Dipeptidyl peptidase IV (DP IV), a functional marker of the T lymphocyte system
3. Possible association of interleukin-2 treatment with depression and suicide
4. Binding of the T cell activation monoclonal antibody TA1 to dipeptidyl peptidase IV
5. Mechanisms of the behavioral effects of interleukin 1
6. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state
7. Early depressive symptoms in cancer patients receiving interleukin-2 and/or interferon alpha therapy
8. Proteases associated with invadopodia, and their role in degradation of extracellular matrix
9. Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin
10. Conversion of substance P to C-terminal fragments in human plasma
11. An assessment of the effects of central interleukin-1beta, -2, -6, and tumor necrosis factor-alpha administration on some behavioural, neurochemical, endocrine and immune parameters in the rat
12. Cytokines and sickness behavior
13. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group
14. Correlations between dipeptidyl peptidase IV and disease activity of rheumatoid arthritis (RA)
15. CD26, let it cut or cut it down
16. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells
17. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects
18. A novel form of dipeptidylpeptidase IV found in human serum; Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26)
19. Dipeptidyl peptidase IV and adenosine deaminase activity. Decrease in depression
20. Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a; implications for the treatment of patients with metastatic melanoma
21. Dipeptidyl peptidase IV and trypsin-like enzymatic degradation of human growth hormone releasing hormone in plasma
22. Serum glycylproline p-nitroanilidase activity in rheumatoid arthritis and systemic lupus erythematosus
23. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma
24. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group
25. Recombinant leukocyte A interferon; Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients
26. A new dipeptide naphthylamidase hydrolyzing glycyl-propyl-a-naphthylamide
27. Is CD26/dipeptidyl peptidase IV a really important molecule in T cell activation of a certain rat strain
28. Suicide associated with alfa-interferon therapy for chronic viral hepatitis
29. The immunobiological effects of interleukin-2 in vivo
30. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma; Clinical data and laboratory evidence of protease activation
31. Glycylprolyl-diaminopeptidase in human leukocytes; Selective occurrence in T lymphocytes and influence on the total serum enzyme activity
32. Regulation of the expression of aminopeptidase A, aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD 26 in renal carcinoma cells and renal tubular epithelial cells by cytokines and cAMP-increasing mediators
33. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma; The Eastern Cooperative Oncology Group Trial EST 1684
34. Brain neurotransmission during peripheral inflammation
35. Major depression and activation of the inflammatory response system
36. Decreased serum dipeptidyl peptidase IV activity in major depression
37. Components of biological variation in plasma prolyl endopeptidase and dipeptidyl peptidase activity in healthy man
38. Dipeptidyl peptidase serum activity in treatment resistant depression; Relationships with immune-inflammatory markers
39. Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock
40. Cytokines for psychologists; implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition
41. Expression of CD26 (Dipeptidyl peptidase IV) on resting and activated human lymphocytes-T
42. In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2
43. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
44. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV
45. A new depression scale designed to be sensitive to change
46. New chromogenic substrates for X-Pro dipeptidyl aminopeptidase
47. CD26 mediates the action of HIV-1 Tat protein on DNA synthesis and cytokine production in U937 cells
48. Stimulation of the expression and the enzyme activity of aminopeptidase N/CD 13 and dipeptidylpeptidase IV/CD 26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell-derived cytokines, such as IL-4 and IL-13
49. Human thymocyte dipeptidyl peptidase IV (CD26) activity is altered with stage of ontogeny
50. Reduced preference for sucrose in autoimmune mice; A possible role of interleukin-6
51. Serum DPP IV activity in transplant recipients
52. Potentiation of the immune response in HIV-1+ individuals
53. A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection
54. Interleukin 2 production by human T lymphocytes identified by antibodies to dipeptidyl peptidase IV
55. Dipeptidyl peptidase IV in human T lymphocytes
56. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men
57. Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV
58. The effects of interferon-alpha on the production and action of other cytokines
59. Decreased expression and release of dipeptidyl peptidase IV (CD26) in cultured peripheral blood T lymphocytes of oral cancer patients
60. Mood and cognitive side effects of interferon-alpha therapy
61. Management of psychiatric adverse events with immunotherapy with interferon-alpha
62. Distribution of proline-specific aminopeptidases in human tissues and body fluids
63. Proline motifs in peptides and their biological processing
64. The psychological and psychiatric effects of rIL-2 therapy; a controlled clinical trial
65. Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15
66. Endotoxin produces a depressive-like episode in rats
67. Behavioral and psychological effect of immune activation; Implications for depression due a general medical condition
68. Neuropeptide Y; Implications in vascular remodeling and novel therapeutics